Sisram Medical Ltd. · HKEX:1696
Sisram Medical — FY2025 Earnings Presentation
27 slides from Sisram Medical's earnings presentation, March 2026
Slide 1: Sisram Medical 2025 Annual Earnings Presentation
Sisram Medical 2025 Annual Earnings Presentation Stock Code: 1696.HK 1
Slide 2: Disclaimer
Disclaimer This presentation and the accompanying slides (the “Presentation”) which have been prepared by Sisram Medical Ltd (the “Company”) do not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any
Slide 3: 2025 Snapshot
2025 Snapshot US$ 365.3 M US$ 28.0 M US$ 254.3 M US$ 147.4M +4.7% YoY +185.6 % YoY +20.1% YoY +26.9 % YoY Revenue from International Markets Revenue from Revenue Injectables (Excl. NA) APAC 58.9 % 8.5 % - 3.2 p.p. YoY +0.3 p.p. YoY Gross Adjusted Net Profit Profit Margin Margin 3
Slide 4: Global Expansion at A Glance
Global Expansion at A Glance Reinforcing our leadership across core and emerging markets, as we continue to scale globally with focus and agility Sustained APAC Growth UK DACH North Europe Ame rica Korea China Japan Israel HK UAE India Thailand Africa Latin Australia America Direct Ma rket s 4
Slide 5: Core Business: EBD Core Products Continue to Surge
Core Business EBD Core Products Continue to Surge ✓ Alma Harmony sales ✓ Alma Hybrid posted its fifth ✓ Successfully launched the remained robust, consecutive year of growth , “钛提升” in China, expanding demonstrating continued underscoring the resilience of our regional product market adoption the Co
Slide 6: Injectables DAXXIFY
Injectables D AXXIFY Key Achievements ✓ In 2025 , DAXXIFY pre - launch preparations in Mainland China progressed steadily, including KOL engagement, sales team readiness, and commercial infrastructure build - out • First FDA approved true innovation in neuromodulator formulation in 30 years ✓ In Jan
Slide 7: Injectables Commercialization Accelerates
Injectables Commercialization Accelerates High - concentration BDDE - free formulation utilizing patented A CE - and FDA - approved hyaluronic acid (HA) NAHYCO® technology, featuring one of the highest dermal filler line helping to rejuvenate the skin, concentrations of hyaluronic acid (HA) on the m
Slide 8: Expanding AI-Enabled Offerings
Expanding AI - Enabled Offerings Al - enabled diagnostics and personalized skincare solutions strengthening our holistic ecosystem A whole new diagnostic product segment has A first - of - its - kind, AI - powered personalized emerged via the introduction of Alma IQ skincare system 8
Slide 9: Strategic Pipeline Development
Strategic Pipeline Development Silk Fibroin 9
Slide 10: Leading the Forefront of Innovation in the Aesthetics World
Leading the Forefront of Innovation in the Aesthetics World Legacy of delivering disruptive Continue investing in technology A unique breakthroughs that redefines the future multidisciplinary that redefine clinical and with 30% of the R&D pipeline dedicated setup driving breakthrough technological e
Slide 11: Enhancing R&D Capabilities
Enhancing R&D Capabilities From IP and Clinical Validation to Rapid Commercialization • Strengthened IP portfolio with patents in ultrasound and laser - assisted liposuction, patent applications in ultrasound and RF, and additional industrial design and trademark registrations • Published a peer - r
Slide 12: Global Brand Leadership and Momentum
Global Brand Leadership and Momentum G lobal leading energy - based device (EBD) brand, trusted by professionals and consumers alike Recognized by professionals as Harmony Bio - Boost gained global recognition, winning Best Laser for Fine Lines at the ELLE Awards High Quality · Trusted Harmony Produ
Slide 13: 2026 Key Initiatives
2026 Key Initiatives Expanding Ecosystem O ffering • Scale flagship EBD platforms, and advance the global launch and upgrade of energy - based devices and handpieces to meet evolving market demand • Accelerate DAXXIFY commercialization in Mainland China and advance premium injectables for further di
Slide 14: Financial Review
Financial Review
Slide 15: 2025 Financials
2025 Financials • Revenue increased by 4.7% YoY in 2025. Growth was driven by robust international expansion of 20.1% outside North America, which recorded a cyclical slowdown, with APAC growing 26.9%, led by China and Thailand • Gross profit margin declined to 58.9%, mainly due to changes in geogra
Slide 16: Financials: Revenue Breakdown by Geography
Latin America 3.8 % Europe 202 5 Middle East and Africa 15.4% North America 111,010 137,398 Financials 10.0% APAC 116,215 147,419 50,538 Europe 56,442 Middle East and 34,605 R evenue Breakdown Africa 36,422 by G eography North Latin America 10,356 14,054 APAC America 40.4% 30.4% 2024 2025 US$ thousa
Slide 17: Financials: Revenue Breakdown by Segments
202 5 • Medical Aesthetics products, led by flagship platforms including Soprano, Harmony, Opus, Accent, and Hybrid, contributed for 85.0% of total revenue, with sales increasing to US$310.4 million , primarily driven by the strong performance of the Harmony product family Financials • Injectables r
Slide 18: 2025 Financials: OPEX Analysis
2025 Financials OPEX Analysis • Adopted prudent financial practices to enhance operational efficiency across mature direct offices, demonstrating agility in adjusting the OPEX structure in response to market fluctuations • The slight YoY increase of US$ 1.57 million in operating expenses was primari
Slide 19: Appendix
Appendix
Slide 20: Advancing Sisram's Consumer-Centric Beauty and Wellness Ecosystem
Advancing Sisram ’s Consumer - Centric Beauty and Wellness Ecosystem Through synergistic business segments Pr od uc ts Our Mission Empowering aesthetics practitioners with state - of - the - art, clinically proven, holistic wellness solutions - spanning energy - based devices, injectables, diagnosti
Slide 21: Capturing Growth Across High-Expansion Medical Aesthetics Segments
Capturing Growth Across High - Expansion Medical Aesthetics Segments Medical aesthetics market size and CAGR 70 64 7 CAGR 58 6.6 53 6.1 12.1 Other 4% - 6% 48 11.1 5.7 44 10.2 40 5.4 9.3 Cosme - 8% - 11% 36 5 ceuticals 33 4.7 8.5 Our new growth 30 4.4 7.8 28 4 7.2 32.2 35.5 drivers beyond EBD 3.7 6.6
Slide 22: Comprehensive Product and Service Solutions Across Key Aesthetics Segments
Comprehensive Product and Service Solutions Across Key Aesthetics Segments C ore Business B2B2C Key Development B2B2C Offer skin boosters, dermal fillers and a A world leading provider of medical aesthetics energy - based device next - generation botulinum toxins AI - Enabled Complementary Solutions
Slide 23: EBD Product Portfolio
EBD Product Portfolio Body BeautiFill by LipoLife Alma PrimeX Accent Alma Prime PrimeX Sk in Alma Harmony Opus Alma Hybrid ALMA Q Pixel CO 2 Derma REJUVE Clear 23
Slide 24: EBD Product Portfolio (Cont.)
EBD Product Portfolio (Cont.) Hair Soprano Titanium Alma TED Soprano SE +20% power Alma Duo FemiLift Sexual Wellness 24
Slide 25: Injectables Product Portfolio
Injectables Product Portfolio Building on extensive clinical experience with energy - based devices , Sisram is strengthening the synergy between EBD and injectables —offering professional customers a unique combination of treatment modalities that delivers enhanced aesthetics outcome s and a superi
Slide 26: Scaling Through Our Global Direct Sales Infrastructure
Scaling Through Our Global Direct Sales Infrastructure Most direct sales offices have entered the growth stage 1 2 3 4 Growth stages of a direct office Incubation stage Formation stage Growth stage Maturity stage Minimal revenue Very high sales growth High sales growth Moderate sales growth Minimal
Slide 27: Sisram Medical 1696.HK
As of 31st December 202 5 Fosun Pharma Public 2196.HK Shareholders 600196.SH 71.42 % 28. 58 % Sisram Medical 1696.HK 100 % 27